Seminars in Thoracic and Cardiovascular Surgery
Volume 19, Issue 2 , Pages 135-141, Summer 2007

Frontiers in Emphysema Research

  • Victor Kim, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania.
    • Corresponding Author InformationAddress reprint requests to Victor Kim, MD, Assistant Professor of Medicine, Temple University School of Medicine, 785 Parkinson Pavilion, 3401 North Broad St, Philadelphia, PA 19140.
  • ,
  • Thomas J. Rogers, PhD

      Affiliations

    • Fels Institute for Cancer Research and Molecular Biology, Center for Substance Abuse Research, Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania.
  • ,
  • Gerard J. Criner, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania.

published online 03 August 2007.

Chronic obstructive pulmonary disease (COPD) is a complex inflammatory disease with a myriad of pulmonary and nonpulmonary disease manifestations. COPD is a heterogeneous disease consisting of emphysematous destruction, airway inflammation, remodeling, and obstruction. Once conceptualized as a unidimensional disease isolated to the lung, it is now recognized to have significant systemic manifestations, such as osteoporosis, cardiovascular disease, and skeletal muscle wasting. As the clinical phenotypic expressions of COPD become more precisely characterized, so does the pathogenesis of this disease. Great strides are now being made in our understanding of genetic susceptibility, airway inflammation, the immune response to cigarette smoke, and inflammatory biomarkers. This review will discuss the most recent progress on selected topics in COPD pathogenesis, inflammation, and genetics. With time, we hope to expand our current understanding to predict who will develop disease and who will not, and why some patients develop particular disease phenotypes. In addition, we hope to clarify the inflammatory mechanisms involved in order to develop novel therapies and identify disease biomarkers that will lead to better tools for monitoring disease activity. Finally, we hope to develop treatments aimed at lung regeneration and repair, to reverse lung damage that has already occurred. We are optimistic that novel therapies like gene therapy and advanced antiinflammatory agents will be in our future. Judging by the progress made in the last decade, these tools may soon become a reality.

Keywords: emphysema, COPD, chronic airflow obstruction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1043-0679(07)00085-8

doi:10.1053/j.semtcvs.2007.05.005

Seminars in Thoracic and Cardiovascular Surgery
Volume 19, Issue 2 , Pages 135-141, Summer 2007